A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWERCSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6


Por: Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG and Rischin D

Publicada: 1 ene 2025 Ahead of Print: 1 dic 2024
Resumen:
Background: In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC). Objectives: To report final analysis of weight-based cemiplimab in mCSCC and laCSCC (groups 1 and 2), fixed-dose cemiplimab in mCSCC (group 3), and primary analysis of fixed-dose cemiplimab in mCSCC/laCSCC (group 6). Methods: Patients received cemiplimab (3 mg/kg intravenously every 2 weeks [groups 1 and 2]) or cemiplimab (350 mg intravenously [groups 3 and 6]) every 3 weeks. The primary end point was objective response rate (ORR). Duration of response (DOR) and progression-free survival (PFS) are presented per protocol, according to post-hoc sensitivity analyses that only include the period of protocol-mandated imaging assessments. Results: At 42.5 months, ORR for groups 1-3 (n = 193) was 47.2%, estimated 12-month DOR was 88.3%, and median PFS was 26.0 months. At 8.7 months, ORR for group 6 (n = 165 patients) was 44.8%; median DOR and median PFS were not reached. Serious treatment-emergent adverse event rates (grade $ 3) were groups 1-3: 31.1% and group 6: 34.5%. Limitations: Nonrandomized study, nonsurvival primary end point. Conclusion: EMPOWER-CSCC-1 provides the largest prospective data on long-term efficacy and safety for anti-programmed cell death-1 therapy in advanced CSCC.

Filiaciones:
Hughes BGM:
 Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

 Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia

Guminski A:
 Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia

Bowyer S:
 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

Migden MR:
 Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas

Schmults CD:
 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Khushalani NI:
 Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida

Chang ALS:
 Department of Dermatology, Stanford University School of Medicine, Redwood City, California

Grob JJ:
 Aix Marseille University, Hôpital de la Timone, Marseille, France

Lewis KD:
 University of Colorado Denver Cancer Center, Aurora, Colorado

Ansstas G:
 Department of Surgical Oncology, Washington University School of Medicine, St Louis, Missouri

Day F:
 Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia

Ladwa R:
 Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia

 Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

Stein BN:
 Adelaide Cancer Centre, Adelaide, South Australia, Australia

Muñoz Couselo E:
 Department of Medical Oncology, Melanoma and Other Skin Tumors Unit, Vall d'Hebron University Hospital, Barcelona, Spain

Meier F:
 Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

 Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany

Hauschild A:
 Department of Dermatology, University Hospital (UKSH), Kiel, Germany

Schadendorf D:
 Department of Dermatology, University Hospital of Essen, Essen, Germany

 German Cancer Consortium, Partner Site Essen, NCT-West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany

Basset-Seguin N:
 Hôpital Saint-Louis, Paris, France

Modi B:
 Division of Dermatology, Department of Surgery, City of Hope, Duarte, California

Dalac-Rat S:
 Hospital Center University Dijon Bourgogne, Dijon, France

Dunn LA:
 David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, New York

Flatz L:
 University Hospital Tübingen, Tübingen, Germany

Mortier L:
 Centre Hospitalier Régional Universitaire de Lille (CHRU), Lille, France

Guégan S:
 Department of Dermatology, Hôpital Cochin, Paris, France

Heinzerling LM:
 Department of Dermatology, LMU University Hospital Munich, Munich, Germany

 Department of Dermatology, University Hospital Erlangen, Erlangen, Germany

Mehnert JM:
 Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health, New York, New York

Trabelsi S:
 CHU de Grenoble - Hôpital A Michallon, Grenoble, France

Soria-Rivas A:
 Ramón y Cajal University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain

Stratigos AJ:
 First Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece

 National and Kapodistrian University of Athens Medical School, Athens, Greece

Ulrich C:
 Charite-Universitatsmedizin Berlin, Berlin, Germany

Wong DJ:
 UCLA Department of Medicine, Los Angeles, California

Beylot-Barry M:
 Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France

Bossi P:
 Department of Biomedical Sciences, Humanitas University, Milan, Italy

 IRCCS Humanitas Research Hospital, Milan, Italy

:
 Department of Medical Oncology, Skin Tumors Unit, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Barcelona, Spain

 Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Barcelona, Spain

Chandra S:
 Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Robert C:
 Gustave Roussy Cancer Center, Villejuif, France

Russell JS:
 Head and Neck/Cutaneous Medical Oncology, Huntsman Cancer Institute, Salt Lake City, Utah

Silk AW:
 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Booth J:
 Regeneron Pharmaceuticals, Inc., Tarrytown, New York

Yoo SY:
 Regeneron Pharmaceuticals, Inc., Tarrytown, New York

Seebach F:
 Regeneron Pharmaceuticals, Inc., Tarrytown, New York

Lowy I:
 Regeneron Pharmaceuticals, Inc., Tarrytown, New York

Fury MG:
 Regeneron Pharmaceuticals, Inc., Tarrytown, New York

Rischin D:
 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
ISSN: 01909622





Journal of the American Academy of Dermatology
Editorial
Mosby Inc., 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 92 Número: 1
Páginas: 68-77
WOS Id: 001392928800001
ID de PubMed: 39245360

MÉTRICAS